• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

    35.86 UNCHANGED
    Streaming Delayed Price Updated: 7:00 PM EDT, May 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Teva Pharmaceutical Industries Limited American Depositary Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    33 34 Next >
    News headline image
    Teva to Present at the BofA Securities Health Care Conference
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't? ↗
    A significant financing deal with Blackstone underscores that the Teva of today isn't the Teva of the past. 
    Via The Motley Fool
    News headline image
    Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Pharmaceutical's Turnaround Is Working. Here's When to Buy the Stock. ↗
    That's when its first-quarter results will be published. 
    Via The Motley Fool
    News headline image
    3 Catalysts That Could Send Teva Stock to $40 and Beyond ↗
    This once-beaten-down pharma stock remains an intriguing turnaround story. 
    Via The Motley Fool
    News headline image
    Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics
    Supplemental funding helps 11 free & charitable clinics and charitable pharmacies expand mental health care and reach more patients in underserved communities 
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology
    Date: April 7, 2026 Introduction Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has long been a bellwether for the mid-cap biotechnology sector, serving as a primary case study in how a company can... 
    Via Finterra
    Topics Earnings Economy Intellectual Property
    News headline image
    Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally
    In a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF... 
    Via MarketMinute
    Topics ETFs Intellectual Property Stocks
    News headline image
    Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough
    The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the... 
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    The Second Act: A Deep-Dive into Corcept Therapeutics and the FDA Approval of Lifyorli
    March 26, 2026 Introduction Yesterday, March 25, 2026, Corcept Therapeutics (NASDAQ: CORT) reached a defining milestone that has fundamentally altered its investment profile: the early FDA approval of... 
    Via Finterra
    Topics Economy Intellectual Property
    News headline image
    This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition ↗
    Masimo develops advanced noninvasive monitoring technologies used by hospitals and healthcare providers worldwide. 
    Via The Motley Fool
    News headline image
    Teva Releases Q1 2026 Aide Memoire
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    The $1.3 Trillion Architect: How Blackstone is Redefining Global Finance through Private Credit and Essential Consumerism
    By Finterra Editorial TeamMarch 18, 2026 Introduction In the high-stakes world of global alternative asset management, one name looms larger than the rest: Blackstone Inc. (NYSE: BX). As of March 18,... 
    Via Finterra
    Topics Artificial Intelligence Economy Energy
    News headline image
    Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment ↗
    This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned ↗
    This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)
    As of March 10, 2026, the biopharmaceutical sector is witnessing a historic realignment in the neurology space, spearheaded by the Canadian-born clinical powerhouse Xenon Pharmaceuticals Inc. (Nasdaq:... 
    Via Finterra
    Topics Economy Initial Public Offering Intellectual Property
    News headline image
    The 3 Best Stocks to Invest $1,000 in Right Now ↗
    These three high-quality stocks have ample growth potential. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Forget Teva: This Dividend Top Dog Is the Real Value Buy Today ↗
    Teva is undergoing a major business transition, but dividend investors should check out this 6.3% yielding competitor instead. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Billionaire Stanley Druckenmiller Dumped 2 of His Top Performers -- Teva and Taiwan Semiconductor -- and Made This Sector-Based ETF His Fund's New No. 2 Holding ↗
    Duquesne Family Office's billionaire boss meaningfully pared down two high-flying stocks in the fourth quarter and made a $301 million wager on a popular sector-based exchange-traded fund (ETF). 
    Via The Motley Fool
    Topics Artificial Intelligence ETFs Retirement
    News headline image
    Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive
    As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent... 
    Via Finterra
    Topics Economy Initial Public Offering Retirement
    News headline image
    The Best Healthcare Stock to Invest $1,000 in Right Now ↗
    There's nothing generic about this drugmaker's recent performance and continued prospects. 
    Via The Motley Fool
    News headline image
    Here's Why I Won't Touch Teva Pharmaceutical With a 10‑Foot Pole ↗
    Sorry, Teva, it's not you ... it's me. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy
    As of February 26, 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a defining crossroads. For years, the company was viewed by many on Wall Street as a "value trap"—a debt-laden giant formed from the... 
    Via Finterra
    Topics Economy
    News headline image
    Bridger Dumps 301,000 Bath & Body Works Shares Worth $7.7 Million ↗
    This specialty retailer delivers personal care and home fragrance products through a broad network of stores and online channels. 
    Via The Motley Fool
    Topics Economy Regulatory Compliance
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    33 34 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.